News

EMVO informs, that prototype and first phase of development for AMS HUB has been completed. AMS HUB solution is currently under system test by provider (started at September 17). Next milestone would be production pilot phase – October 4.

The Latvian Medicines Verification System (LZVS) has successfully passed all compatibility tests so that the Latvian national system is prepared for European Medicines Verification System (EU Hub) updates / system release 1.9. LZVS is ready to work without interruption and restriction

On 13 January 2021, the European Commission adopted a new Delegated Regulation, amending Delegated Regulation (EU) 2016/161 as regards a derogation from the obligation of wholesalers to decommission the unique identifier of products exported to the United Kingdom.

European Medicines Verification Organisation (EMVO) was published frequently asked questions regarding verification system and Brexit.

Attesting their qualification and high operating standards of the LZVO, more and more specialists of the Latvian Medicines Verification Organisation (LZVO) hold positions at the international level.

EMVO has been working to manage the implications of Brexit (the UK’s departure from the EU Internal Market rules) for the EMVS and its users.